EXACT SCIENCES (EXAS) Company Report

Exact Sciences stockholders have approved the proposed acquisition of Exact Sciences by Abbott.
Over 99% of the votes cast, representing approximately 67% of the total outstanding shares as of the January 9, 2026 record date, were in favor of the transaction.
The acquisition is expected to close before the end of the second calendar quarter of 2026.
Upon completion, Exact Sciences' stockholders will receive $105.00 in cash for each share of common stock.

7 days ago

Press Release

Exact Sciences Stockholders Approve Merger Agreement with Abbott Laboratories

EXAS

M&A

Proxy Vote Outcomes

Executive Compensation

Exact Sciences Corporation held a special meeting on February 20, 2026, where stockholders voted on proposals related to the merger with Abbott Laboratories.
Stockholders approved the merger agreement proposal with Abbott Laboratories.
The advisory, non-binding proposal regarding executive compensation related to the merger was not approved by stockholders.
The merger transaction is expected to be completed before the end of the second quarter of calendar year 2026.

7 days ago

Transcript

Exact Sciences Stockholders Approve Merger Agreement

EXAS

M&A

Proxy Vote Outcomes

Executive Compensation

Exact Sciences' stockholders have approved the merger agreement proposal with Abbott Laboratories and Badger Merger Sub I Inc..
The advisory, non-binding proposal regarding compensation for named executive officers related to the merger was not approved by stockholders.
The merger transaction is anticipated to be completed before the end of the second quarter of calendar year 2026.
As of January 9th, 2026, there were 190,810,202 shares of Exact's common stock outstanding and entitled to vote.

7 days ago

Transcript

Exact Sciences Stockholders Approve Merger Agreement

EXAS

M&A

Proxy Vote Outcomes

Executive Compensation

Exact Sciences' stockholders held a special meeting on February 20, 2026, to vote on proposals related to a merger with Abbott Laboratories and Badger Merger Sub One Inc..
The merger agreement proposal was approved by stockholders.
The advisory, non-binding proposal regarding executive compensation related to the merger was not approved.
The merger transaction is expected to be completed before the end of the second quarter of calendar year 2026.

7 days ago

Transcript

Exact Sciences Reports Q4 and Full-Year 2025 Results

EXAS

Earnings

Revenue Acceleration/Inflection

Product Launch

Exact Sciences reported Q4 revenue of $878.4 million and full-year 2025 revenue of approximately $3.25 billion.
The company significantly narrowed its losses, with a Q4 net loss of $86.0 million (EPS -$0.45) and a full-year 2025 net loss of roughly $207.9 million (EPS -$1.10).
For 2025, Exact Sciences achieved a gross profit of $2,262.76 million and a gross margin of 69.7%.
Operational progress in 2025 included the launch of three new tests (Cologuard Plus, Oncodetect, and Cancerguard) and expanded lab capacity.

Feb 13, 2026, 9:15 PM

Morningstar

Exact Sciences Announces Record Q4 and Full Year 2025 Results and Provides Merger Update

EXAS

Earnings

M&A

Revenue Acceleration/Inflection

Exact Sciences reported record total revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year 2025, representing increases of 23% and 18% respectively.
For the full year 2025, the company recorded a net loss of $208 million and adjusted EBITDA of $400 million, with operating cash flow of $491 million and free cash flow of $357 million.
The company is proceeding with its pending merger with Abbott Laboratories, with a special stockholder meeting scheduled for February 20, 2026, to adopt the Merger Agreement.
The merger is anticipated to close in the second quarter of 2026, subject to obtaining required regulatory approvals and other customary closing conditions.

Feb 13, 2026, 9:06 PM

8-K

Exact Sciences Announces Record Q4 and Full Year 2025 Results and Provides Merger Update

EXAS

Earnings

Product Launch

M&A

Exact Sciences reported record total revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year 2025, representing increases of 23% and 18% respectively.
For the full year 2025, the company achieved operating cash flow of $491 million and free cash flow of $357 million, alongside an adjusted EBITDA of $400 million.
Strategic advancements in 2025 included the launch of three new tests, positive clinical results for Oncodetect® and Oncoguard® Liver tests, and acquiring exclusive U.S. rights to Freenome’s blood-based colorectal cancer screening tests.
Exact Sciences entered into a Merger Agreement with Abbott Laboratories on November 19, 2025, with a special stockholder meeting scheduled for February 20, 2026, and is working towards closing the merger in the second quarter of 2026.

Feb 13, 2026, 9:05 PM

Press Release

Exact Sciences provides supplemental disclosures regarding Abbott merger amidst stockholder lawsuits

EXAS

M&A

Legal Proceedings

Guidance Update

Exact Sciences Corporation (EXAS) is proceeding with its merger with Abbott Laboratories, as agreed on November 19, 2025, which will result in Exact becoming a direct, wholly owned subsidiary of Abbott.
As of February 10, 2026, three lawsuits have been filed by purported stockholders in New York State court, alleging deficiencies in the definitive proxy statement for the merger.
To address these claims and minimize potential delays or costs, Exact Sciences has voluntarily made supplemental disclosures in this 8-K filing, without admitting liability or wrongdoing.
The supplemental disclosures include financial projections, with estimated revenue of $3,245 million for 2025E and $3,730 million for 2026E, and adjusted EBITDA of $410 million for 2025E and $700 million for 2026E.

Feb 10, 2026, 9:05 PM

8-K

Exact Sciences' Patent Claims Against Geneoscopy Invalidated

EXAS

Legal Proceedings

The Patent Trial and Appeal Board (PTAB) has issued a Final Written Decision finding all 10 challenged claims of Exact Sciences’ U.S. Patent No. 11,970,746 (the ‘746 patent) unpatentable.
This decision follows a July 2025 PTAB ruling that invalidated all 20 claims of Exact Sciences’ U.S. Patent No. 11,634,781 (the ‘781 patent).
As a result, all patent claims asserted by Exact Sciences against Geneoscopy in their ongoing litigation have now been invalidated by the PTAB.
This outcome removes patent hurdles for Geneoscopy to advance the commercialization of its ColoSense® RNA-based noninvasive colorectal cancer screening test.
Geneoscopy has also filed counterclaims against Exact Sciences alleging breach of contract, misappropriation of trade secrets, false advertising, and unfair competition.

Feb 6, 2026, 9:03 PM

Press Release

Exact Sciences Applauds Passage of Medicare Coverage Legislation for Multi-Cancer Early Detection Tests

EXAS

New Projects/Investments

Exact Sciences announced the passage of landmark federal legislation that establishes a pathway for Medicare coverage of multi-cancer early detection (MCED) tests.
This legislation, based on the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, creates a clear coverage framework for MCED tests following U.S. Food and Drug Administration (FDA) approval and subsequent Centers for Medicare & Medicaid Services (CMS) implementation.
The company views this as a critical step to expand access to this emerging technology for millions of Medicare beneficiaries.
Exact Sciences is developing its Cancerguard test, a laboratory-developed test (LDT) designed to detect multiple cancers from a blood draw, which is currently under clinical evaluation and has not yet been cleared or approved by the FDA.

Feb 3, 2026, 7:32 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for EXACT SCIENCES.

Q3 2025

Nov 3, 2025

→

Q2 2025

Aug 6, 2025

→

Q1 2025

May 1, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kevin Conroy say about margins?What are EXACT SCIENCES's strategic priorities?How is EXACT SCIENCES positioned vs competitors?How did EXACT SCIENCES do last quarter?

EXACT SCIENCES (EXAS)

Analyst Earnings Quarterly Reports

Q4 2020

Q1 2020

Q3 2019

Q1 2017

Executives

Kevin Conroy

Aaron Bloomer

Brian Baranick

Jacob Orville

James Herriott

Sarah Condella

Board Members

D. Scott Coward

Daniel Levangie

James Doyle

Katherine Zanotti

Kimberly Popovits

Leslie Trigg

Michael Barber

Paul Clancy

Shacey Petrovic

Analyst Coverage

Andrew Brackmann

Daniel Brennan

Matthew Sykes

Patrick Donnelly

Puneet Souda

Subhalaxmi Nambi

Tycho Peterson

Vijay Kumar

Douglas Schenkel

Jack Meehan

Andrew Cooper

Daniel Leonard

Daniel Arias

Eve Burstein

Mark Massaro

William Bonello

Catherine Ramsey

Catherine Schulte

Kyle Mikson

Luke Sergott

Sung Ji Nam

Brandon Couillard

Michael Ryskin

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent